LIFECORE BIOMEDICAL, INC. \DE\ — Form SCHEDULE 13D/A
Filed September 29, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
On September 27, 2026, Wynnefield-affiliated entities and individuals (holding ~8.6M common shares + ~16.7M shares on preferred conversion) executed a Voting and Support Agreement with Lifecore Inc. and Lifecore Biomedical. Stockholders commit to vote all covered shares in favor of the merger with Hazel Merger Sub, lock up shares from transfer, waive appraisal rights, and refrain from solicitation activities. The agreement binds all future share acquisitions and terminates only at closing or merger termination.
Why this rating
Standard pre-merger voting agreement with key shareholders (~97% ownership estimated). Deal structure and terms unknown; voting commitment is procedural, not transformational. Scale relative to $223M market cap is material but typical M&A governance.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.